Tonix Pharmaceuticals Advances TNX-102 SL into Phase 2 Trial for Major Depressive Disorder — Tonix Pharmaceuticals Holding Corp.

Event summary

Tonix Pharmaceuticals has enrolled the first patient in its Phase 2 HORIZON study of TNX-102 SL for Major Depressive Disorder (MDD).
The trial is a randomized, double-blind, placebo-controlled study with a primary endpoint of change from baseline in MADRS total score at Week 6.
TNX-102 SL was previously approved by the FDA in August 2025 for fibromyalgia under the brand name TONMYA®.
The study aims to enroll approximately 360 patients across 30 sites in the United States.

The big picture

Tonix Pharmaceuticals is leveraging the existing approval of TNX-102 SL for fibromyalgia to explore its potential in treating Major Depressive Disorder, a condition affecting over 21 million U.S. adults annually. The Phase 2 HORIZON study represents a strategic pivot into the mental health space, where there is significant unmet need for first-line therapies with better tolerability profiles. Success in this trial could position Tonix as a key player in the CNS disorder market.

What we're watching

Clinical Efficacy: Whether TNX-102 SL can demonstrate significant improvement in depressive symptoms and sleep quality compared to placebo.
Regulatory Pathway: The pace at which Tonix can advance TNX-102 SL through subsequent clinical trials and potential FDA approval for MDD.
Market Opportunity: How successful commercialization of TNX-102 SL for MDD could expand Tonix's revenue streams beyond its current fibromyalgia indication.